HIMS turns to loss in Q3 and lowers earnings guidance, Hyperliquid perpetual contract drops over 10% at one point
BIBIBI
AT A GLANCE
According to reports, Hims & Hers saw revenue growth in Q3 but net profit turned to a loss; after lowering earnings guidance, HIMS perpetual contracts dropped by about 10.4% at one point.
Article
HIMS revenue and net profit turn to losses after earnings report, on-chain price briefly dips 10%
BlockBeats News, November 10, Hims & Hers released its third-quarter earnings today. The company's quarterly revenue increased by 49% year-over-year to 890000000 USD, but the gross margin decreased from 74% in the same period last year to 57%, and net profit turned from a profit of 15800000 USD to a loss of 33000000 USD.
Earnings guidance was also lowered. The company reduced its full-year 2026 adjusted EBITDA expectation from the previous range of 275000000 to 325000000 USD to 257000000 to 277000000 USD, with the midpoint of the guidance decreasing by approximately 11%. Full-year revenue guidance was narrowed to 3130000000 to 3150000000 USD.
According to TradingBeats monitoring, following the release of the earnings report, HIMS perpetual contracts on Hyperliquid experienced a significant wick. Around 05:08, the trading price briefly dropped to 20.57 USD, down about 10.4% from 22.95 USD before the announcement; it then quickly recovered, rising back above 23 USD within about half an hour.
As of press time, the contract was temporarily reported at approximately 22.14 USD, down about 14.8% in the past 24 hours and still about 3.6% lower than before the earnings release; trading volume over the same period was approximately 11430000 USD, with a nominal open interest value of approximately 3220000 USD.
In contrast, Moderna contracts rose by about 5.9% to 271.66 USD during the same period. Moderna announced its third-quarter net profit of approximately 162000000 USD on November 6 and raised its full-year revenue growth expectation from no more than 10% to 15%—25%.
Original link https://m.theblockbeats.info/flash/376504
Key points
01
According to BlockBeats, Hims & Hers' Q3 revenue increased by 49% year-over-year to 890000000 USD, while the gross margin fell from 74% in the same period last year to 57%.
02
The company's quarterly net profit turned from a profit of 15800000 USD to a loss of 33000000 USD.
03
Full-year 2026 adjusted EBITDA expectations were lowered from 275000000 to 325000000 USD to 257000000 to 277000000 USD, with the guidance midpoint decreasing by approximately 11%; full-year revenue guidance was narrowed to 3130000000 to 3150000000 USD.
04
According to TradingBeats monitoring, following the earnings release, HIMS perpetual contracts on Hyperliquid briefly fell to 20.57 USD around 05:08, down about 10.4% from 22.95 USD before the announcement, and recovered above 23 USD within about half an hour.
05
As of the time of writing, HIMS contracts were reported at approximately 22.14 USD, down about 14.8% in the past 24 hours and about 3.6% lower than before the earnings release; trading volume over the same period was approximately 11430000 USD, with a nominal open interest value of approximately 3220000 USD.
06
The report also noted that Moderna contracts rose by about 5.9% to 271.66 USD during the same period; Moderna announced its Q3 net profit of approximately 162000000 USD on November 6 and raised its full-year revenue growth expectation from no more than 10% to 15%—25%.
AI-assisted interpretation
The following is analysis, separate from reported facts. Verify important claims independently.
The focus of this report is not a decline in revenue, but rather the decrease in gross margin and the shift of net profit from positive to negative despite revenue growth, along with the company's reduction in full-year adjusted EBITDA expectations. HIMS perpetual contracts experienced a sharp short-term drop followed by a quick recovery after the earnings release, but remained below pre-announcement prices at press time. The wording of the title can be confusing, as the body does not state that revenue declined.
Why it matters to readers
The divergence between revenue growth and profitability is key to understanding this earnings report; the short-term low, rebound price, and press-time price of the contract should not be conflated.
Do not equate revenue growth with profit growth, nor treat Hyperliquid perpetual contract prices directly as US stock spot prices; the text does not provide HIMS US stock spot prices.
Risks and unknowns
The material consists of media retellings and does not provide original financial statements or independent market data; financial figures and contract market conditions have not been independently verified.
The body does not explain the specific reasons for the decrease in gross margin, the shift of net profit to a loss, and the lowering of earnings guidance.
There is a temporal sequence between the earnings release and contract volatility, but the material is insufficient to confirm that the entire drop was caused by the earnings report, nor does it explain the cause of the wick.
Related Developments
Loading event timeline…
Market data in the text has specific time references; press-time quotes do not represent current prices.
Related concepts
Gross profit margin
This term is not in the glossary yet. Browse related concepts in the glossary.
A derivative contract with no expiration date, designed for continuous holding, whose funding rate mechanism helps keep its price close to that of the underlying asset.
